Shun Lu

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1836959/shun-lu-publications-by-year.pdf
Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

219 papers	11,493 citations	32 h-index	105 g-index
256 ext. papers	15,586 ext. citations	5.6 avg, IF	5.94 L-index

#	Paper	IF	Citations
219	Tagrisso incremental therapy in a case of meningeal metastasis of lung cancer with EGFR mutation: a case report.. *Translational Lung Cancer Research*, **2022**, 11, 323-330	4.4	0
218	Convergent alteration of lung tissue microbiota and tumor cells in lung cancer.. *IScience*, **2022**, 25, 103638	6.1	0
217	Phase I Trial of a Third Generation EGFR Mutant-Selective Inhibitor (D-0316) in Patients with Advanced Non-Small Cell Lung Cancer.. *Oncologist*, **2022**, 27, 163-e213	5.7	1
216	Treatment preferences for epidermal growth factor receptor mutation-positive non-small cell lung cancer with brain metastasis: a large-scale survey from Chinese oncologists.. *Annals of Translational Medicine*, **2022**, 10, 41	3.2	
215	Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial.. *BMC Medicine*, **2022**, 20, 42	11.4	0
214	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.. *International Journal of Clinical Oncology*, **2022**, 27, 695-706	4.2	0
213	Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non-Small Cell Lung Cancer.. *Cancer Journal (Sudbury, Mass.)*, **2022**, 28, 96-104	2.2	
212	FGF19 Is Coamplified With CCND1 to Promote Proliferation in Lung Squamous Cell Carcinoma and Their Combined Inhibition Shows Improved Efficacy.. *Frontiers in Oncology*, **2022**, 12, 846744	5.3	0
211	The relationship between different subtypes of and PD-L1 & tumor mutation burden (TMB) based on next-generation sequencing (NGS) detection in Chinese lung cancer patients.. *Translational Lung Cancer Research*, **2022**, 11, 213-223	4.4	0
210	Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.. *New England Journal of Medicine*, **2022**,	59.2	59
209	AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With Exon 19 Deletion or L858R Mutations.. *Journal of Clinical Oncology*, **2022**, JCO2102641	2.2	4
208	Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients.. *Journal of Hematology and Oncology*, **2022**, 15, 62	22.4	1
207	Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison. *Journal of Clinical Medicine*, **2022**, 11, 2963	5.1	0
206	NLRP4 negatively regulates type I interferon response and influences the outcome in anti-PD-1/PD-L1 therapy.. *Cancer Science*, **2021**,	6.9	1
205	Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer.. *Lung Cancer*, **2021**, 165, 71-81	5.9	0
204	Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. *Journal of Thoracic Oncology*, **2021**,	8.9	11
203	Diverse responses to EGFR-TKIs in patients with concurrent germline and somatic EGFR mutations. *Lung Cancer*, **2021**, 162, 207-209	5.9	0

202	A multi-omics-based serial deep learning approach to predict clinical outcomes of single-agent anti-PD-1/PD-L1 immunotherapy in advanced stage non-small-cell lung cancer. *American Journal of Translational Research (discontinued)*, **2021**, 13, 743-756	3	8
201	Pyrotinib in Patients with -Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial. *Clinical Cancer Research*, **2021**,	12.9	5
200	Predictable Roles of Peripheral IgM Memory B Cells for the Responses to Anti-PD-1 Monotherapy Against Advanced Non-Small Cell Lung Cancer.. *Frontiers in Immunology*, **2021**, 12, 759217	8.4	2
199	Efficacy of Aumolertinib (HS-10296) in Patients with Advanced EGFR T790M+ NSCLC: Updated Post NMPA-approval Results from the APOLLO Registrational Trial. *Journal of Thoracic Oncology*, **2021**,	8.9	13
198	Propensity score matched analysis for the role of surgery in stage III small cell lung cancer based on the eighth edition of the TNM classification: a population study of the US SEER database and a Chinese hospital. *Lung Cancer*, **2021**, 162, 54-60	5.9	0
197	A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer. *Future Oncology*, **2021**, 17, 4827-4835	3.6	0
196	Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC. *Cancer Medicine*, **2021**, 10, 2286-2292	4.8	1
195	Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence. *Advances in Therapy*, **2021**, 38, 2038-2053	4.1	6
194	Hexokinase 2 discerns a novel circulating tumor cell population associated with poor prognosis in lung cancer patients. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	13
193	Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). *Lung Cancer*, **2021**, 154, 176-185	5.9	3
192	Plasma mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer. *Annals of Translational Medicine*, **2021**, 9, 635	3.2	3
191	AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, 2021, 39, TPS9108-TPS9108	2.2	3
190	Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. *JAMA Oncology*, **2021**, 7, 709-717	13.4	45
189	RATIONALE-307: Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥65.. *Journal of Clinical Oncology*, **2021**, 39, 9102-9102	2.2	1
188	Serum Metabolite Biomarkers Predictive of Response to PD-1 Blockade Therapy in Non-Small Cell Lung Cancer. *Frontiers in Molecular Biosciences*, **2021**, 8, 678753	5.6	5
187	Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).. *Journal of Clinical Oncology*, **2021**, 39, 9013-9013	2.2	8
186	Chinese advanced fusion-dependent lung cancer patients: Molecular spectrum and treatment options using next generation sequencing: A multicenter study (Yangtze River Delta Lung Cancer Cooperation Group-001).. *Journal of Clinical Oncology*, **2021**, 39, e21036-e21036	2.2	
185	Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2021**, 39, 8503-8503	2.2	29

184	Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review. *Annals of Translational Medicine*, **2021**, 9, 950	3.2	2
183	International consensus on severe lung cancer-the first edition. *Translational Lung Cancer Research*, **2021**, 10, 2633-2666	4.4	2
182	Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With V600E Mutation: A Case Report. *Frontiers in Oncology*, **2021**, 11, 634920	5.3	2
181	Mini-patient-derived xenograft assay based on microfluidic technology promises to be an effective tool for screening individualized chemotherapy regimens for advanced non-small cell lung cancer. *Cell Biology International*, **2021**, 45, 1887-1896	4.5	3
180	Integrated Analysis of Genomic and Immunological Features in Lung Adenocarcinoma With Micropapillary Component. *Frontiers in Oncology*, **2021**, 11, 652193	5.3	1
179	Clonal Architecture of Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641). *Clinical Cancer Research*, **2021**, 27, 704-712	12.9	7
178	Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078). *Lung Cancer*, **2021**, 152, 7-14	5.9	13
177	Standardization of pleural effusion-based tumor mutation burden (TMB) estimation using capture-based targeted sequencing. *Annals of Translational Medicine*, **2021**, 9, 140	3.2	2
176	Peripheral CD4 T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer. *Science China Life Sciences*, **2021**, 64, 1590-1601	8.5	2
175	Distinct profile of cell-free DNA in malignant pleural effusion of non-small cell lung cancer and its impact on clinical genetic testing. *International Journal of Medical Sciences*, **2021**, 18, 1510-1518	3.7	2
174	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. *Lancet Oncology, The*, **2021**, 22, 198-211	21.7	244
173	Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study. *Translational Lung Cancer Research*, **2021**, 10, 839-854	4.4	1
172	Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study, CTONG-0904): an open-label, randomized, phase III trial. *Annals of Translational Medicine*, **2021**, 9, 338	3.2	1
171	Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial. *JTO Clinical and Research Reports*, **2021**, 2, 100142	1.4	
170	Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study. *Journal of Thoracic Oncology*, **2021**, 16, 1959-1963	8.9	1
169	Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress. *Clinical Lung Cancer* , **2021**, 22, 371-375	4.9	7
168	Immunochemotherapy as First-line Treatment for Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancers-Reply. *JAMA Oncology*, **2021**, 7, 1580-1581	13.4	1
167	Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study. *Journal of Thoracic Oncology*, **2021**, 16, 1403-1414	8.9	0

166	Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3). *Future Oncology*, **2021**, 17, 4237-4247	3.6	3
165	The Chinese Thoracic Oncology Group (CTONG) therapeutic option scoring system: a multiple-parameter framework to assess the value of lung cancer treatment options. *Translational Lung Cancer Research*, **2021**, 10, 3594-3607	4.4	0
164	Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial. *BMC Cancer*, **2021**, 21, 1033	4.8	1
163	Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. *Cancer Cell*, **2021**, 39, 1279-1291.e3	24.3	20
162	Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial. *Journal of Thoracic Oncology*, **2021**, 16, 1512-1522	8.9	24
161	Knockdown of CDK5 down-regulates PD-L1 via the ubiquitination-proteasome pathway and improves antitumor immunity in lung adenocarcinoma. *Translational Oncology*, **2021**, 14, 101148	4.9	2
160	Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. *Lancet Respiratory Medicine,the*, **2021**, 9, 1154-1164	35.1	14
159	Modelled Economic Analysis for Dacomitinib-A Cost Effectiveness Analysis in Treating Patients With EGFR-Mutation-Positive Non-Small Cell Lung Cancer in China.. *Frontiers in Oncology*, **2021**, 11, 564234	5.2	0
158	Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic. *Journal of Thoracic Oncology*, **2020**, 15, 1119-1136	8.9	51
157	Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort. *Translational Lung Cancer Research*, **2020**, 9, 269-279	4.4	25
156	FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer. *Cell Adhesion and Migration*, **2020**, 14, 82-95	3.2	9
155	Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study.	4.8	3
154	Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. *Lancet Respiratory Medicine,the*, **2020**, 8, 1132-1143	35.1	66
153	A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study. *Lung Cancer*, **2020**, 146, 252-262	5.9	4
152	First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer. *Cancer Medicine*, **2020**, 9, 3310-3318	4.8	10
151	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. *Journal of Thoracic Oncology*, **2020**, 15, 914-947	8.9	71
150	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. *Journal of Thoracic Oncology*, **2020**, 15, 709-740	8.9	77
149	Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104. *Oncogene*, **2020**, 39, 3507-3521	9.2	16

148	Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge. *Science China Life Sciences*, **2020**, 63, 1499-1514	8.5	12
147	Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.. *Journal of Clinical Oncology*, **2020**, 38, 9501-9501	2.2	87
146	Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+).. *Journal of Clinical Oncology*, **2020**, 38, 9519-9519	2.2	30
145	Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC).. *Journal of Clinical Oncology*, **2020**, 38, 9554-9554	2.2	2
144	A phase I study to evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TQ-B3101.. *Journal of Clinical Oncology*, **2020**, 38, e21705-e21705	2.2	3
143	Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage NSCLC. *Journal of Thoracic Oncology*, **2020**, 15, 176-189	8.9	17
142	The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis. *Translational Lung Cancer Research*, **2020**, 9, 1770-1784	4.4	8
141	A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER. *Frontiers in Oncology*, **2020**, 10, 578756	5.3	17
140	Immuno-based therapeutic strategies for initial unresectable locally advanced non-small cell lung cancer: a case report. *Translational Lung Cancer Research*, **2020**, 9, 803-806	4.4	
139	PAK5 promotes the cell stemness ability by phosphorylating SOX2 in lung squamous cell carcinomas. *Experimental Cell Research*, **2020**, 395, 112187	4.2	2
138	Adverse Effects of Combined Tyrosine Kinase Inhibitors. *Journal of Thoracic Oncology*, **2020**, 15, e182-e183	8.9	
137	MicroRNA-214-3p inhibits the stem-like properties of lung squamous cell cancer by targeting YAP1. *Cancer Cell International*, **2020**, 20, 413	6.4	6
136	Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. *Journal of Thoracic Oncology*, **2020**, 15, 1907-1918	8.9	36
135	Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer. *New England Journal of Medicine*, **2020**, 383, 1711-1723	59.2	335
134	Liquid biopsy-based single-cell metabolic phenotyping of lung cancer patients for informative diagnostics. *Nature Communications*, **2019**, 10, 3856	17.4	21
133	Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer. *Oncogenesis*, **2019**, 8, 50	6.6	26
132	Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring exon 14 skipping mutation: a case report. *OncoTargets and Therapy*, **2019**, 12, 7323-7328	4.4	11
131	Durable Clinical Response of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in trans-C797S to Combination Therapy of First- and Third-Generation EGFR Tyrosine Kinase Inhibitors. *Journal of Thoracic Oncology*, **2019**, 14, e157-e159	8.9	10

130	Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors. *Oncologist*, **2019**, 24, S21-S30	5.7	16
129	Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology. *Cancer Biology and Medicine*, **2019**, 16, 189-204	5.2	12
128	The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging. *Oncology Reports*, **2019**, 41, 2636-2646	3.5	4
127	Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib. *OncoTargets and Therapy*, **2019**, 12, 1521-1538	4.4	3
126	Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules: A non-invasive biomarker for predicting malignancy and tumour invasiveness. *EBioMedicine*, **2019**, 41, 236-243	8.8	18
125	MiR-516a-5p inhibits the proliferation of non-small cell lung cancer by targeting HIST3H2A. *International Journal of Immunopathology and Pharmacology*, **2019**, 33, 2058738419841481	3	8
124	Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. *Lung Cancer*, **2019**, 132, 126-131	5.9	17
123	Exosomal miR-499a-5p promotes cell proliferation, migration and EMT via mTOR signaling pathway in lung adenocarcinoma. *Experimental Cell Research*, **2019**, 379, 203-213	4.2	47
122	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. *Lancet, The*, **2019**, 393, 1819-1830	40	1272
121	Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma. *Thoracic Cancer*, **2019**, 10, 839-847	3.2	16
120	EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer. *Journal of Thoracic Oncology*, **2019**, 14, 732-736	8.9	22
119	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. *Journal of Thoracic Oncology*, **2019**, 14, 867-875	8.9	141
118	Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study. *Lung Cancer*, **2019**, 130, 18-24	5.9	4
117	Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study. *Cancer Management and Research*, **2019**, 11, 6543-6552	3.6	3
116	The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC. *Journal of Thoracic Oncology*, **2019**, 14, 1378-1389	8.9	150
115	Klotho is identified as a target for theranostics in non-small cell lung cancer. *Theranostics*, **2019**, 9, 7474-7489	12.4	7
114	Crizotinib versus pemetrexed-based chemotherapy in patients with advanced ROS1-rearranged non-small cell lung cancer.. *Journal of Clinical Oncology*, **2019**, 37, 9101-9101	2.2	2
113	CANOPY-A: A phase III study of canakinumab as adjuvant therapy in patients with surgically resected non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2019**, 37, TPS8570-TPS8570	2.2	2

112	The CANOPY program: Canakinumab in patients (pts) with non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2019**, 37, TPS9124-TPS9124	2.2	10
111	Prevalence of exon 14 skipping mutation in pulmonary sarcomatoid carcinoma patients without common targetable mutations: A single-institute study. *Journal of Cancer Research and Therapeutics* , **2019**, 15, 909-913	1.2	11
110	Development and validation of a deep learning model to assess tumor progression to immunotherapy.. *Journal of Clinical Oncology*, **2019**, 37, e20601-e20601	2.2	1
109	Efficacy and safety of IBI305 compared with bevacizumab in advanced non-squamous NSCLC patients as first-line treatment in a randomized, double-blind, phase III study.. *Journal of Clinical Oncology*, **2019**, 37, 9095-9095	2.2	
108	The compound mutations in Chinese advanced non-small cell lung cancer patients. *Cancer Biology and Therapy*, **2019**, 20, 1097-1104	4.6	7
107	First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. *Journal of Cancer Research and Clinical Oncology*, **2019**, 145, 1569-1579	4.9	24
106	Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer. *Translational Lung Cancer Research*, **2019**, 8, 989-999	4.4	16
105	Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations: afatinib in ERBB+ lung squamous cell carcinoma. *Anti-Cancer Drugs*, **2019**, 30, 873-878	2.4	3
104	Distribution of NRG1 Gene Fusions in a Large Population of Chinese Patients with NSCLC. *Journal of Thoracic Oncology*, **2019**, 14, e263-e266	8.9	4
103	FGA isoform as an indicator of targeted therapy for EGFR mutated lung adenocarcinoma. *Journal of Molecular Medicine*, **2019**, 97, 1657-1668	5.5	7
102	Prognostic significance of anaplastic lymphoma kinase rearrangement in patients with completely resected lung adenocarcinoma. *Journal of Thoracic Disease*, **2019**, 11, 4258-4270	2.6	7
101	Lung squamous cell carcinoma: A postoperative recurrence analysis of keratinizing and nonkeratinizing subtypes. *European Journal of Surgical Oncology*, **2019**, 45, 838-844	3.6	4
100	PD-1 blockade augments humoral immunity through ICOS-mediated CD4 T cell instruction. *International Immunopharmacology*, **2019**, 66, 127-138	5.8	10
99	Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer. *Lung Cancer*, **2019**, 127, 19-24	5.9	20
98	Inhibiting proliferation and migration of lung cancer using small interfering RNA targeting on Aldo-keto reductase family 1 member B10. *Molecular Medicine Reports*, **2018**, 17, 2153-2160	2.9	9
97	The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer. *Cancer Letters*, **2018**, 423, 36-46	9.9	35
96	Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient. *Lung Cancer*, **2018**, 123, 83-86	5.9	12
95	Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPAR/PTEN/mTOR signaling pathway. *BMC Cancer*, **2018**, 18, 407	4.8	18

94	Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance. *Cancer Communications*, **2018**, 38, 19	9.4	10
93	Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2018**, 13, 1539-1548	8.9	85
92	A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.. *Journal of Clinical Oncology*, **2018**, 36, 9025-9025	2.2	20
91	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. *Translational Lung Cancer Research*, **2018**, 7, 428-436	4.4	5
90	Mutation profiling and treatment choosing of Chinese ROS1 positive advanced lung cancer patients.. *Journal of Clinical Oncology*, **2018**, 36, e21102-e21102	2.2	1
89	Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). *Patient*, **2018**, 11, 131-141	3.7	12
88	Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*, **2018**, 36, 1405-1411	2.2	152
87	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*, **2018**, 36, 1207-1217	2.2	17
86	A Randomized Controlled Study of rhTPO and rhIL-11 for the Prophylactic Treatment of Chemotherapy-Induced Thrombocytopenia in Non-Small Cell Lung Cancer. *Journal of Cancer*, **2018**, 9, 4718-4725	4.5	5
85	Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring mutations: subgroup analysis of the LUX-Lung 6 trial. *OncoTargets and Therapy*, **2018**, 11, 8575-8587	4.4	16
84	Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung. *OncoTargets and Therapy*, **2018**, 11, 8565-8573	4.4	7
83	SIRT6 drives epithelial-to-mesenchymal transition and metastasis in non-small cell lung cancer via snail-dependent transrepression of KLF4. *Journal of Experimental and Clinical Cancer Research*, **2018**, 37, 323	12.8	26
82	Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response. *Cancer Communications*, **2018**, 38, 60	9.4	25
81	Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies. *Lung Cancer*, **2018**, 126, 1-8	5.9	28
80	Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China. *PLoS ONE*, **2018**, 13, e0205827	3.7	17
79	Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung - A Multicenter, Open-label, Randomized, Phase III Trial. *Journal of Thoracic Oncology*, **2018**, 13, 1743-1749	8.9	7
78	Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2018**, 13, 987-995	8.9	45
77	FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer. *Oncogene*, **2018**, 37, 5340-5354	9.2	66

76	High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 2544-2549	11.5	53
75	A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel. *ESMO Open*, **2017**, 2, e000174	6	3
74	Genome-wide DNA Methylation Analysis Reveals as a Novel Epigenetic Target for 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment. *Clinical Cancer Research*, **2017**, 23, 5003-5014	12.9	7
73	FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells. *Journal of Experimental and Clinical Cancer Research*, **2017**, 36, 72	12.8	29
72	Evaluation of the VeriStrat serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. *Lung Cancer*, **2017**, 109, 101-108	5.9	24
71	EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. *British Journal of Cancer*, **2017**, 116, 175-185	8.7	61
70	Integrated discovery of FOXO1-DNA stabilizers from marine natural products to restore chemosensitivity to anti-EGFR-based therapy for metastatic lung cancer. *Molecular BioSystems*, **2017**, 13, 330-337		7
69	Correlation of clinicopathologic features and lung squamous cell carcinoma subtypes according to the 2015 WHO classification. *European Journal of Surgical Oncology*, **2017**, 43, 2308-2314	3.6	9
68	Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. *Oncotarget*, **2017**, 8, 9996-10006	3.3	32
67	Clinic application of tissue engineered bronchus for lung cancer treatment. *Journal of Thoracic Disease*, **2017**, 9, 22-29	2.6	10
66	Tumor invasiveness defined by IASLC/ATS/ERS classification of ground-glass nodules can be predicted by quantitative CT parameters. *Journal of Thoracic Disease*, **2017**, 9, 1190-1200	2.6	21
65	Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status. *Scientific Reports*, **2017**, 7, 8483	4.9	3
64	Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer. *Lung Cancer*, **2017**, 111, 43-50	5.9	1
63	Design and implementation of a mobile system for lung cancer patient follow-up in China and initial report of the ongoing patient registry. *Oncotarget*, **2017**, 8, 5487-5497	3.3	3
62	Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis. *Oncotarget*, **2017**, 8, 53675-53683	3.3	8
61	A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. *Oncotarget*, **2017**, 8, 41474-41486	3.3	12
60	Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expression. *Oncotarget*, **2017**, 8, 79703-79711	3.3	1
59	XBP1-LOX Axis is critical in ER stress-induced growth of lung adenocarcinoma in 3D culture. *American Journal of Translational Research (discontinued)*, **2017**, 9, 700-707	3	5

58	Differential crizotinib efficacy among ROS1 fusion partners in ROS1-positive non-small cell lung cancer.. *Journal of Clinical Oncology*, **2017**, 35, 9067-9067	2.2	
57	Phase III study of NEPA, a fixed combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV).. *Journal of Clinical Oncology*, **2017**, 35, 10090-10090	2.2	1
56	Association of circulating tumor DNA clearance during treatment with improved progression-free survival in advanced non-small cell lung cancer patients.. *Journal of Clinical Oncology*, **2017**, 35, 11528-11528	2.2	
55	Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. *Clinical Lung Cancer*, **2016**, 17, e103-e112	4.9	10
54	Economic analysis of ALK testing and crizotinib therapy for advanced non-small-cell lung cancer. *Pharmacogenomics*, **2016**, 17, 985-94	2.6	18
53	Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2016**, 34, 9022-9022	2.2	14
52	First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).. *Journal of Clinical Oncology*, **2016**, 34, 9046-9046	2.2	10
51	Phase 3 study of first-line crizotinib vs pemetrexed□isplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2016**, 34, 9058-9058	2.2	6
50	Integrated In Silico-In Vitro Discovery of Lung Cancer-related Tumor Pyruvate Kinase M2 (PKM2) Inhibitors. *Medicinal Chemistry*, **2016**, 12, 613-620	1.8	11
49	Genome-wide screen of DNA methylation study in stage IIIa (N2) EGFR 19 deletion adenocarcinoma with erlotinib treatment.. *Journal of Clinical Oncology*, **2016**, 34, e20067-e20067	2.2	
48	SIRT2 inhibits non-small cell lung cancer cell growth through impairing Skp2-mediated p27 degradation. *Oncotarget*, **2016**, 7, 18927-39	3.3	30
47	A novel paclitaxel-loaded poly(d,l-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment. *International Journal of Nanomedicine*, **2016**, 11, 2119-31	7.3	13
46	FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the Hedgehog pathway. *Oncotarget*, **2016**, 7, 15118-34	3.3	35
45	Identification of FGF19 as a prognostic marker and potential driver gene of lung squamous cell carcinomas in Chinese smoking patients. *Oncotarget*, **2016**, 7, 18394-402	3.3	25
44	An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer. *Asia-Pacific Journal of Clinical Oncology*, **2016**, 12, 380-387	1.9	3
43	Frequencies of ALK rearrangements in lung adenocarcinoma subtypes: a study of 2299 Chinese cases. *SpringerPlus*, **2016**, 5, 894		12
42	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. *Lancet Oncology, The*, **2016**, 17, 577-89	21.7	691
41	Prognostic value of MMP9 activity level in resected stage I B lung adenocarcinoma. *Cancer Medicine* , **2016**, 5, 2323-31	4.8	10

40	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. *Lancet Oncology, The*, **2015**, 16, 141-51	21.7	1081
39	TERT Polymorphism rs2736100-C Is Associated with EGFR Mutation-Positive Non-Small Cell Lung Cancer. *Clinical Cancer Research*, **2015**, 21, 5173-5180	12.9	34
38	SEMA4B inhibits growth of non-small cell lung cancer in vitro and in vivo. *Cellular Signalling*, **2015**, 27, 1208-13	4.9	39
37	An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer. *Biochimie*, **2015**, 112, 111-20	4.6	20
36	Maintenance Therapy Improves Survival Outcomes in Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of 14 Studies. *Lung*, **2015**, 193, 805-14	2.9	13
35	Different roles of myofibroblasts in the tumorigenesis of nonsmall cell lung cancer. *Tumor Biology*, **2015**, 37, 15525	2.9	1
34	A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer. *Journal of Thoracic Oncology*, **2015**, 10, 206-11	8.9	25
33	Transforming growth factor-1-induced epithelial to mesenchymal transition increases mitochondrial content in the A549 non-small cell lung cancer cell line. *Molecular Medicine Reports*, **2015**, 11, 417-21	2.9	12
32	Isolation and characterization of ex vivo expanded mesenchymal stem cells obtained from a surgical patient. *Molecular Medicine Reports*, **2015**, 11, 1777-83	2.9	3
31	Detection and correlation analysis of serum cytokines in non-small-cell lung cancer patients with bone and non-bone metastases. *Patient Preference and Adherence*, **2015**, 9, 1165-9	2.4	4
30	BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*, **2015**, 33, 2197-204	2.2	224
29	Clinical analysis of 95 cases of pulmonary sarcomatoid carcinoma. *Biomedicine and Pharmacotherapy*, **2015**, 76, 134-40	7.5	27
28	NF-B-mediated miR-124 suppresses metastasis of non-small-cell lung cancer by targeting MYO10. *Oncotarget*, **2015**, 6, 8244-54	3.3	66
27	Inhibition of the growth of non-small cell lung cancer by miRNA-1271. *American Journal of Translational Research (discontinued)*, **2015**, 7, 1917-24	3	13
26	Role of WNT1-inducible-signaling pathway protein 1 in etoposide resistance in lung adenocarcinoma A549 cells. *International Journal of Clinical and Experimental Medicine*, **2015**, 8, 14962-8		
25	Regulation of catenin-mediated esophageal cancer growth and invasion by miR-214. *American Journal of Translational Research (discontinued)*, **2015**, 7, 2316-25	3	11
24	A survival comparison study of Chinese patients with primary lung adenocarcinoma harboring ALK rearrangements with crizotinib treatment detected by FISH, IHC, and RT-PCR.. *Journal of Clinical Oncology*, **2015**, 33, e19135-e19135	2.2	0
23	Effect of intercalated erlotinib with gemcitabine/cisplatin as neoadjuvant treatment in stage IIIA unrectable non-small cell lung cancer (CTONG 1101, NCT01297101) on disease-free survival: A single arm, multi-center, phase II study.. *Journal of Clinical Oncology*, **2015**, 33, e18519-e18519	2.2	

22	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. *Lancet Oncology, The*, **2014**, 15, 213-22	21.7	1395
21	Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer. *Lung Cancer*, **2014**, 85, 401-7	5.9	23
20	The polycomb group protein EZH2 inhibits lung cancer cell growth by repressing the transcription factor Nrf2. *FEBS Letters*, **2014**, 588, 3000-7	3.8	33
19	The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis. *OncoTargets and Therapy*, **2014**, 7, 387-93	4.4	17
18	Everolimus and zoledronic acid--a potential synergistic treatment for lung adenocarcinoma bone metastasis. *Acta Biochimica Et Biophysica Sinica*, **2014**, 46, 792-801	2.8	10
17	FBXL5-mediated degradation of single-stranded DNA-binding protein hSSB1 controls DNA damage response. *Nucleic Acids Research*, **2014**, 42, 11560-9	20.1	23
16	Continuation of afatinib beyond progression: Results of a randomized, open-label, phase III trial of afatanib plus paclitaxel (P) versus investigator's choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and afatanib□UX-Lung 5 (LL5).. *Journal of Clinical Oncology*, **2014**, 32, 8019-8019	2.2	16
15	Molecular epidemiology of EGFR mutations in 7,953 non-small cell lung cancer of Chinese ethnicity.. *Journal of Clinical Oncology*, **2014**, 32, e19009-e19009	2.2	1
14	Meta-analysis for curative effect of lobectomy and segmentectomy on non-small cell lung cancer. *International Journal of Clinical and Experimental Medicine*, **2014**, 7, 2599-604		8
13	Formononetin suppresses the proliferation of human non-small cell lung cancer through induction of cell cycle arrest and apoptosis. *International Journal of Clinical and Experimental Pathology*, **2014**, 7, 8453-61	1.4	24
12	Acetylcholine receptor pathway in lung cancer: New twists to an old story. *World Journal of Clinical Oncology*, **2014**, 5, 667-76	2.5	17
11	Prognostic significance of the extent of lymph node involvement in stage II-N1 non-small cell lung cancer. *Chest*, **2013**, 144, 1253-1260	5.3	19
10	LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung.. *Journal of Clinical Oncology*, **2013**, 31, 8016-8016	2.2	26
9	Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2012**,	2.2	26
8	Randomized phase II study of recombinant human endostatin in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer (NCT00912392).. *Journal of Clinical Oncology*, **2012**, 30, 7091-7091	2.2	
7	Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *Lancet Oncology, The*, **2011**, 12, 735-42	21.7	3028
6	Maintenance Therapy for NSCLC: Consensus and Controversy. *Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research*, **2011**, 23, 254-8	3.8	6
5	Sirtuin expression is downregulated in non-small cell lung cancer. *FASEB Journal*, **2010**, 24, 567.3	0.9	

4	Perioperative chemotherapy of stage III N2 non-small cell lung cancer. *Chinese-German Journal of Clinical Oncology*, **2009**, 8, 185-189		
3	The effects of cetuximab alone and in combination with endostatin on vascular endothelial growth factor and interleukin-8 expression in human lung adenocarcinoma cells. *Current Therapeutic Research*, **2009**, 70, 116-28	2.4	4
2	Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice. *Oncology Reports*, **2008**, 20, 581-7	3.5	21
1	The relationship between the pathological changes and response rate (RR) in non-small cell lung cancer treated by neoadjuvant chemotherapy with mitomycin (MMC), vindesine (VDS) and cisplatin (DDP) combination. *Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research*, **2000**, 12, 220-223	3.8	